Vancouver, BC – March 08, 2017 -InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference, which is being held March 12-15, 2017, at the Ritz Carlton, Laguna Niguel, California.
"The ROTH Conference is one of the largest in the nation, and it does a wonderful job introducing small and mid-cap companies to institutional investors who are focused on these emerging opportunities, said Chris Bogart, SVP of Investor Relations. InMed Pharmaceuticals is honored to have been asked to present this assembly of Institutional investors who represent significant resources in the healthcare space, and we believe InMed Pharmaceuticals is a very well positioned, high potential opportunity."
About ROTH Capital Conference
ROTH Capital Partners 29th Annual Conference is one of the largest of its kind in the U.S. Following the success of previous years’ events, the ROTH Conference, with close to 500 participating companies and over 4,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors including Healthcare. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a ‘must attend’ event for anyone working in the small and mid-cap space. ROTH combines company presentations, Q&A sessions and management one-on-one meetings so that institutional investors can have an in-depth look at company senior management and issues affecting the growth of the presenting companies.
ROTH is an investment banking firm dedicated to the small-cap public market. Since its inception in 1984, ROTH has been an innovator in this market. Headquartered in Newport Beach, CA, ROTH has regional offices in Boston, Chicago, Larkspur, Los Angeles, New York and San Diego as well as Hong Kong.
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com
Contact: InMed Pharmaceuticals Inc.
SVP, Investor Relations and Corporate Strategy
Forward Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about the company’s positioning as a high potential opportunity in the Healthcare sector and the expected fundamental value drivers of the company. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Known risk factors include, among others: InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.